Original Article

You have full text access to this OnlineOpen article

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma †‡

  1. David J. Samson B.A.1,§,*,
  2. Jerome Seidenfeld Ph.D.2,
  3. Brian Schmitt M.D.3,
  4. Vic Hasselblad Ph.D.4,
  5. Peter C. Albertsen M.D.5,
  6. Charles L. Bennett M.D., Ph.D.6,7,
  7. Timothy J. Wilt MD., M.P.H.8,
  8. Naomi Aronson Ph.D.2

Article first published online: 11 JUL 2002

DOI: 10.1002/cncr.10647

Issue

Cancer

Cancer

Volume 95, Issue 2, pages 361–376, 15 July 2002

Additional Information

How to Cite

Samson, D. J., Seidenfeld, J., Schmitt, B., Hasselblad, V., Albertsen, P. C., Bennett, C. L., Wilt, T. J. and Aronson, N. (2002), Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma . Cancer, 95: 361–376. doi: 10.1002/cncr.10647

Author Information

  1. 1

    Technology Evaluation Center, Blue Cross and Blue Shield Association, Washington, DC

  2. 2

    Technology Evaluation Center, Blue Cross and Blue Shield Association, Chicago, Illinois

  3. 3

    VA Chicago Health Care System, Lakeside Division, Chicago, Illinois

  4. 4

    Duke Clinical Research Institute, Durham, North Carolina

  5. 5

    Division of Urology, University of Connecticut Health Center, Farmington, Connecticut

  6. 6

    VA Chicago Health Care System, Lakeside Division, Midwest Center for Health Services Policy and Research, Chicago, Illinois

  7. 7

    Robert A. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois

  8. 8

    Department of General Internal Medicine, VA Medical Center, Minneapolis, Minnesota

  1. §

    Fax: (202) 626-4833

*Blue Cross and Blue Shield Association, 1310 G Street NW, Washington, DC 20005

  1. †

    This work was developed under contract with the Agency for Healthcare Research and Quality (AHRQ contract number 290-97-0015). The Blue Cross and Blue Shield Association Technology Evaluation Center is an Evidence-Based Practice Center of the AHRQ.

  2. ‡

    Charles L. Bennett has received grants from Schering-Plough and Astra-Zeneca and has acted as a consultant for Schering-Plough.

Publication History

  1. Issue published online: 11 JUL 2002
  2. Article first published online: 11 JUL 2002
  3. Manuscript Accepted: 15 JAN 2002
  4. Manuscript Revised: 7 JAN 2002
  5. Manuscript Received: 9 MAY 2001

Funded by

  • Schering-Plough
  • Astra-Zeneca

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (131K)

REFERENCES

  • 1
    Labrie F, Dupont A, Belanger A, et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med. 1982; 5 (4): 267-275.
  • 2
    Labrie F, Dupont A, Belanger A, et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem Mol Biol. 1985; 23 (5B): 833–841.
  • 3
    Schroder FH. Is there a best endocrine treatment of prostate cancer? J Clin Endocrinol Metab. 1995; 80 (4): 1071–1074.
  • 4
    Fitzpatrick JM. Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument against. Eur Urol. 1996; 29 (Suppl 2): 37–39.
  • 5
    Goldenberg SL, Bruchovsky N. Androgen withdrawal therapy: new perspectives in the treatment of prostate cancer. In: RhagavanD, ScherRI, LeibelSA, et al., editors. Principles and practice of genitourinary oncology. Philadelphia: Lippincott-Raven, 1997: 583–591.
  • 6
    Debruyne FM. Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument for. Eur Urol. 1996; 29 (Suppl 2): 34–36.
  • 7
    Thrasher JB, Crawford ED. Combined androgen blockade. In: VogelzangNJ, ScardinoPT, ShipleyWU et al., editors. Comprehensive textbook of genitourinary oncology. Baltimore: Williams & Wilkins, 1996: 875–884.
  • 8
    Schellhammer PF. Combined androgen blockade for the treatment of metastatic cancer of the prostate. Urology. 1996; 47 (5): 622–628.
  • 9
    Labrie F, Belanger A, Cusan L, et al. History of LHRH agonist and combination therapy in prostate cancer. Endocrine Rel Cancer. 1996; 3: 243–278.
  • 10
    Iversen P. Combined androgen blockade in the treatment of advanced prostate cancer—an overview. The Scandinavian Prostatic Cancer Group. Scand J Urol Nephrol. 1997; 31 (3): 249–254.
  • 11
    Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000; 355 (9214): 1491–1498.
  • 12
    Hussain MH, Crawford ED. Androgen deprivation strategies for metastatic prostate cancer. In: RhagavanD, ScherRI, LeibelSA, et al., editors. Principles and practice of genitourinary oncology. Philadelphia: Lippincott-Raven, 1997: 591–597.
  • 13
    Caubet JF, Tosteson TD, Dong EW, et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology. 1997; 49: 71–78.
  • 14
    Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Dis. 1999; 2: 4–8.
  • 15
    Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998; 339: 1036–1042.
  • 16
    Moher D, Cook D, Jadad A, et al. Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Health Technol Assess. 1999; 3: 1–98.
  • 17
    MulrowCD, OxmanAD, editors. Cochrane Collaboration Handbook [updated 9 December 1996]. Available in: The Cochrane Library [database on disk and CD-ROM]. The Cochrane Collaboration. Issue 1. Oxford: Update Software, 1997.
  • 18
    Mosteller F, Gilbert JP, McPeek B. Reporting standards and research strategies for controlled trials. Agenda for the editor. Control Clinical Trials. 1980; 1: 37–58.
  • 19
    Andersson L, editor. Design of clinical trials on prostate cancer. Urology. 1997; 49 (Suppl 4A): 1–76.
  • 20
    Aronson N, Seidenfeld J, Samson DJ, et al. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evidence Report/Technology Assessment: Number 4. Rockville (MD): Agency for Health Care Policy and Research; 1999 AHCPR Pub. No. 99-E0012. Available from URL: http:// www.ahcpr.gov/clinic/prossumm.html [accessed date]
  • 21
    Whitehead A, Whitehead J. A general approach to the meta-analysis of randomized clinical trials. Stat Med. 1991; 10: 1665–1677.
    Direct Link:
  • 22
    Hasselblad V. Meta-analysis of multitreatment studies. Med Decis Making. 1998; 18: 37–43.
  • 23
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177–188.
  • 24
    Egret for Windows. Cambridge, MA: Cytel Software Corp., 1999.
  • 25
    de Voogt HJ, Klijn JG, Studer U, Schroder F, Sylvester R, De Pauw M. Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843. J Steroid Biochem Mol Biol. 1990; 37: 965–969.
  • 26
    Ferrari P, Castagnetti G, Ferrari G, Pollastri CA, Tavoni F, Dotti A. Combination treatment in M1 prostate cancer. Cancer. 1993; 72 (12 Suppl): 3880–3885.
    Direct Link:
  • 27
    Ferrari P, Castagnetti G, Ferrari G, Baisi B, Dotti A. Combination treatment versus LHRH alone in advanced prostatic cancer. Urol Int. 1996; 56 (Suppl 1): 13–17.
  • 28
    Bono AV, DiSilverio F, Robustelli della Cuna G, et al. Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group. Urol Int. 1998; 60 (Suppl 1): 18–24.
  • 29
    Schulze H, Kaldenhoff H, Senge T. Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer. Urol Int. 1988; 43: 193–197.
  • 30
    Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989; 321: 419–424
  • 31
    Iversen P, Christensen MG, Friis E, et al. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer. 1990; 66 (5 Suppl): 1058–1066.
  • 32
    Denis LJ, Carnelro de Moura JL,et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology. 1993; 42: 119–129.
  • 33
    Robinson MR, Smith PH, Richards B, Newling DW, de Pauw M, Sylvester R. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol. 1995; 28: 273–283.
  • 34
    Zalcberg JR, Raghaven D, Marshall V, Thompson PJ. Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate—an Australian multicentre trial. Br J Urol. 1996; 77: 865–869.
  • 35
    Beland G, Elhilali M, Fradet Y, et al. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. Cancer. 1990; 66 (5 Suppl): 1074–1079.
  • 36
    Namer M, Toubol J, Caty A, et al. A randomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer. J Steroid Biochem Mol Biol. 1990; 37: 909–915.
  • 37
    Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol. 1997; 158: 160–163.
  • 38
    Brisset JM, Boccon-Gibod L, Botto H, et al. Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo. Prog Clin Biol Res. 1987; 243A: 411–422.
  • 39
    Williams G, Asopa R, Abel PD, Smith C. Pituitary adrenal and gonadal endocrine suppression for the primary treatment of prostate cancer. Br J Urol. 1990; 65: 504–508.
    Direct Link:
  • 40
    Jorgensen T, Tveter KJ, Jorgensen LH. Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No. 2. Eur Urol. 1993; 24: 466–470.
  • 41
    Klosterhalfen H, Becker H. Results of a 10-year randomised prospective study in metastasised prostate cancer. Aktuelle Urol. 1987; 18: 234–236.
  • 42
    Crawford ED, Kasimis BS, Gandara D, et al. A randomized, controlled clinical trial of leuprolide and anandron (LA) vs leuprolide and placebo (LP) for advanced prostate cancer (D2cap) [abstract]. Proc Annu Meet Am Soc Clin Oncol. 1990; 9: A523.
  • 43
    Periti P, Rizzo M, Mazzei T, Mini E. Depot leuprorelin acetate alone or with nilutamide in the treatment of metastatic prostate carcinoma: interim report of a multicenter, double-blind, placebo-controlled study [abstract]. Can J Infect. 1995; 6 (Suppl C): 292C.
  • 44
    Boccardo F, Pace M, Rubagotti A, et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group. Eur J Cancer. 1993; 29A: 1088–1093.
  • 45
    Fourcade RO, Cariou G, Coloby P, et al. Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study. Eur Urol. 1990; 18 (Suppl 3): 45–47.
  • 46
    Tyrrell CJ, Altwein JE, Klippel F, et al. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group. J Urol. 1991; 146: 1321–1326.
  • 47
    Di Silverio F, Serio M, D'Eramo G, Sciarra F. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study. Eur Urol. 1990; 18 (Suppl 3): 54–61.
  • 48
    Schellhammer PF, Sharifi R, Block NL, et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology. 1997; 50: 330–336.
  • 49
    Navratil H. Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study. Prog Clin Biol Res. 1987; 243A: 401–410.
  • 50
    Moinpour CM, Savage M, Lovato L, et al. Quality of life (QOL) endpoints in advanced stage prostate cancer: a randomized, double blind study comparing flutamide to placebo in orchiectomized stage D2 prostate patients (PTS) [abstract]. Proc Annu Meet Am Soc Clin Oncol. 1997; 16: A183.
  • 51
    Moinpour CM, Savage MJ, Troxel A, et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst. 1998; 90: 1537–1544.
  • 52
    Albertsen PC, Aaronson NK, Muller MJ, Keller SD, Ware JD. Health-related quality of life among patients with metastatic prostate cancer. Urology. 1997; 49: 207–217.
  • 53
    da Silva FC, Aaronson N. Quality of life assessment in prostatic cancer. Prog Clin Biol Res. 1988; 260: 1191–21.
  • 54
    da Silva FC, Reis E, Costa T, Denis L. Quality of life in patients with prostatic cancer. A feasibility study. The Members of Quality of Life Committee of the EORTC Genitourinary Group. Cancer. 1993; 71 (3 Suppl): 1138–1142.
    Direct Link:
  • 55
    Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. Nat Cancer Inst. 2000; 92: 1731–1739.
  • 56
    Litwin MS, Lubeck DP, Henning JM, Carroll PR. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol. 1998; 159: 1988–1992.
View Full Article (HTML) Get PDF (131K)